Tertiary cytoreduction for recurrent endometrial cancer

This paper reviews the surgical approach experiences in endometrial cancer recurrence and presents for the first time data on the surgical management of endometrial cancer patients at the time of their second recurrence. Surgery could represent a pivotal role in selected cases of recurrent endometrial cancer, offering long-term complete remissions and a survival advantage.

Recurrent endometrial cancer; Salvage surgery; Metastasectomy.

[1] Papadia A., Bellati F., Ditto A., Bogani G., Gasparri M.L., Di Donato V., Martinelli F., et al.: “Surgical treatment of recurrent endometrial cancer: time for a paradigm shift”. Ann. Surg. Oncol., 2015, 22, 4204.

[2] Scarabelli C., Campagnutta E., Giorda G., DePiero G., Sopracordevole F., Quaranta M., DeMarco L.: “Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma”. Gynecol. Oncol., 1998, 70, 90.

[3] Campagnutta E., Giorda G., De Piero G., Sopracordevole F., Visentin M.C., Martella L., Scarabelli C.: “Surgical treatment of recurrent endometrial carcinoma”. Cancer, 2004, 100, 89.

[4] Awtrey C.S., Cadungog M.G., Leitao M.M., Alektiar K.M., Aghajanian C., Hummer A.J., et al.: “Surgical resection of recurrent endometrial carcinoma”. Gynecol. Oncol., 2006, 102, 480.

[5] Bristow R.E., Santillan A., Zahurak M.L., Gardner G.J., Giuntoli R.L. 2nd, Armstrong D.K.: “Salvage cytoreductive surgery for recurrent endometrial cancer”. Gynecol. Oncol., 2006, 103, 281.

[6] Ren Y., Shan B., Shi D., Wang H.: “Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study”. BMC Cancer, 2014, 14, 135.

[7] Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S.: “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study”. J. Clin. Oncol., 2004, 22, 3902.

[8] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2004, 22, 2159.

[9] Thigpen T., Brady M.F., Homesley H.D., Soper J.T., Bell J.: “Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2001, 19, 364.

[10] Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T.: “Highdose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 1996, 14, 357.

[11] Whitney C.W., Brunetto V.L., Zaino R.J., Lentz S.S., Sorosky J., Armstrong D.K., et al.: “Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 4.

[12] Westin S.N., Rallapalli V., Fellman B., Urbauer D.L., Pal N., Frumovitz M.M., et al.: “Overall survival after pelvic exenteration for gynecologic malignancy”. Gynecol. Oncol., 2014, 134, 546.